Google DeepMind's AlphaGenome Atlas

AlphaGenome Atlas is not a new model but a precomputed answer key: Google DeepMind ran its AlphaGenome model against all 9 billion possible single-letter substitutions in the human genome and stored the results in a roughly 1-petabyte database, more than 30 times the size of the AlphaFold Database^[1]. Every variant gets an AlphaGenome Variant Impact (AVI) score, which folds AlphaGenome's regulatory predictions and AlphaMissense's protein-coding predictions - plus conservation and loss-of-function features - into a single number^[1]. The score is designed to be intuitive: a variant scoring 10 sits in the top 10% most impactful in the genome, and a score of 30 places it among roughly the top 1 in 1,000^[2]. Crucially, the Atlas does not stop at the 2% of the genome that codes for protein - it covers the 98% non-coding portion too, and ships with a catalogue of more than 2,500 recurrent DNA motifs that researchers can browse alongside the variant scores^[3].

The clearest evidence the Atlas works beyond a demo came from the Broad Institute, where researchers used the AVI score to flag an overlooked deep intronic variant in the DNM1 gene, strongly linked to epileptic encephalopathy. AlphaGenome predicted the variant created an incorrect splice site that caused abnormal protein extension - a prediction later confirmed by experimental screens^[1]. DeepMind reports that AVI scoring more than doubles researchers' ability to identify rare-disease-causing mutations compared to the field's previous standard tool^[2]. The pattern held outside DeepMind's own case studies too: a University of Exeter researcher applied the Atlas to more than 54,000 UK Biobank whole genomes and found 22% more non-coding genetic associations than would otherwise have been detectable^[3]. For DeepMind's VP of Science, this is the payoff of finally being able to interpret, not just read, the genome - as he put it, "we bought the book, but we did not understand how to read it"^[4].

Access to the Atlas splits along a line likely to define its next phase. Today it's free for noncommercial academic use through a no-code website portal that DeepMind says requires zero coding skills, plus an API and notebooks on GitHub^[5]. But DeepMind has also signaled a future commercial tier distributed through Google Cloud's Model Garden, with no price or timeline yet disclosed^[7]. Fortune reported that Isomorphic Labs, DeepMind's own drug-discovery affiliate, is named as needing a commercial license to use AlphaGenome - underscoring that the free tier is bounded by use case, not by DeepMind's corporate structure^[4]. One write-up on the coming commercial tier framed it plainly: "Google's genome map comes with a commercial tier later"^[6]. That gap between a landmark resource opened for free research today and a paid enterprise product to follow is also fueling pushback in parts of the research and developer community discussing the launch, where some argue that ultimate control of the roadmap still sits with a for-profit company.

For all its scale, DeepMind's own team is candid about the difficulty of the underlying problem. Genomics Initiative Lead Žiga Avsec has said that when the project began, "it seemed impossible to do that computationally"^[8]. Outside researchers are cautious about how the tool will be used in practice: University of British Columbia's Carl de Boer said the Atlas "has a clear use, but it also is probably going to be easily misinterpreted"^[8]. That caution matters because uptake is already large - roughly 9,000 researchers have accessed AlphaGenome's predictions via API since the underlying model's 2025 release^[9]- meaning any systematic misreading of AVI scores could spread quickly across many labs before the field settles on norms for using single-variant predictions responsibly.